- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05605418
Study of a Comprehensive Intelligent Hypertension managEment SyStem (CHESS)
October 29, 2022 updated by: China National Center for Cardiovascular Diseases
Study of a Comprehensive Intelligent Hypertension managEment SyStem (CHESS) Evaluation in Primary Health Care Settings
This cluster randomized controlled trial aims to evaluate the efficacy of a comprehensive intelligent hypertension management system (CHESS) in blood pressure lowering in primary health care (PHC) settings of China.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
The trial aims to investigate the efficacy of a comprehensive digital intervention for hypertension treatment in cluster clinics.
40 PHC centers will be selected from different areas in China, and eligible patients being screened consecutively in each site, then all PHC centers will be randomized into intervention group and control group.
The physicians and patients from the 20 intervention sites will receive training and support on the use of the CHESS system, and the control group will continue to receive usual care.
The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
All participants will be asked to attend the clinic at least once every 3 months, and be followed up for 12 months.
Study Type
Interventional
Enrollment (Anticipated)
1600
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Haibo Zhang, MD
- Phone Number: +86 60866781
- Email: haibo.zhang@fwoxford.org
Study Contact Backup
- Name: Xiqian Huo, PhD
- Phone Number: +86 60866884
- Email: xiqian.huo@fwoxford.org
Study Locations
-
-
-
Beijing, China
- Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases
-
Contact:
- Haibo Zhang, MD
- Phone Number: +86 60866781
- Email: haibo.zhang@fwoxford.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria for Sites:
- An electronic data collection system is routinely used at the clinic for hypertension management in PHC sites, and the distance between sites must be >2km;
At least one drug of each of the five classes of recommended antihypertensive medications is available at the clinic:
- A: Angiotensin-converting enzyme inhibitors (ACEI; e.g., captopril or enalapril);
- A: Angiotensin receptor blockers (ARB; e.g., losartan or valsartan)
- B: β-blockers (e.g., atenolol, metoprolol, or bisoprolol)
- C: Calcium antagonists (e.g., nitrendipine, nifedipine, or amlodipine)
- D: Diuretics (e.g., hydrochlorothiazide, indapamide, or indapamide SR tablets)
- Has an outpatient clinic for hypertension treatment and staff are willing to take part in the study.
Inclusion Criteria for Participants:
- Age ≥35 years and <80 years
- Local resident of the community/township who attends the PHC clinic for hypertension management, and will not travel for more than 3 months during the study period;
- Established diagnosis of essential hypertension, with uncontrolled BP before randomization (defined as office BP≥140/90mmHg, and 24-hour ambulatory BP≥130/80mmHg);
- Own and be able to use a smartphone daily;
- Be willing to participate in the study and sign the informed consent.
Exclusion Criteria for participants:
- Physician-diagnosed or suspected secondary hypertension (e.g. hypertension caused by renal disease, renal artery stenosis, aortic stenosis, primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid dysfunction, intracranial disease, drug- induced, or rare monogenic genetic disease), or the presence of other structural heart diseases, such as aortic insufficiency, hypertrophic cardiomyopathy, or congenital heart disease;
- Office or ambulatory SBP≥180 mmHg and/or DBP≥110 mmHg before randomization;
- Physician-diagnosed atrial fibrillation;
- Physician-diagnosed CKD, estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 (if serum creatinine is available), or currently on dialysis treatment;
- Physician-diagnosed hepatic dysfunction, or ALT≥ 2*ULN;
- Currently at the unstable or terminal stage of any disease (e.g. new- onset cardiovascular and cerebrovascular diseases occurred within 3 months, malignant tumors);
- Intolerance to at least two classes of antihypertensive medications among A, B, C or D;
- Currently taking 3 or more antihypertensive drugs;
- The subject is pregnant or breastfeeding, or planning to become pregnant or breastfeeding during the study period;
- Have communication or cognitive disorders;
- Be unwilling to take antihypertensive drugs, or assumed poor adherence to treatment;
- The subject is participating in other clinical trials at the moment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CHESS intervention
Physicians and patients at the intervention group will receive training and support on the use of the multi-faceted CHESS system.
|
The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
|
No Intervention: Control
After site randomization, physicians at the control sites will manage their patients by usual care at hypertension clinics.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in 24-hour ambulatory SBP from baseline to 12-month follow up;
Time Frame: Baseline; 12 months
|
The investigators will measure the change in 24-h ambulatory SBP from baseline to 12 months.
|
Baseline; 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean changes in 24-hour ambulatory DBP from baseline to 12-month;
Time Frame: Baseline; 12 months
|
The investigators will measure the change in 24-h ambulatory DBP from baseline to 12 months.
|
Baseline; 12 months
|
Mean changes in office SBP from baseline to 12-month;
Time Frame: Baseline; 12 months
|
Patient's office SBP will be measured at hypertension clinics.
|
Baseline; 12 months
|
Mean changes in office DBP from baseline to 12-month;
Time Frame: Baseline; 12 months
|
Patient's office DBP will be measured at hypertension clinics.
|
Baseline; 12 months
|
Proportion of patients with office BP under control at 12-month;
Time Frame: Baseline; 12 months
|
Office BP under control is defined as blood pressure <130/80 mmHg at hypertension clinic.
|
Baseline; 12 months
|
Proportion of patients with 24-hour ambulatory BP under control (<130/80 mmHg) at 12-month;
Time Frame: Baseline; 12 months
|
Ambulatory BP under control is defined as mean ambulatory BP <130/80 mmHg.
|
Baseline; 12 months
|
Mean changes in 24-hour ABPM heart rate from baseline to 12-month;
Time Frame: Baseline; 12 months
|
The investigators will measure the change in 24-h ambulatory heart rate from baseline to 12 months.
|
Baseline; 12 months
|
Proportion of hypertension visits during which inappropriate antihypertensive treatment is prescribed;
Time Frame: Baseline; 12 months
|
Inappropriate antihypertensive treatment is defined as a prescription incompliant with the pre-specified guideline-based recommendations.
Antihypertensive treatment prescriptions will be measured and obtained through questionnaire and medical records information and be compared with decision support system recommendations automatically.
|
Baseline; 12 months
|
Change in patients' medication adherence of antihypertensive drugs;
Time Frame: Baseline; 12 months
|
The investigators will measure patients medication adherence using information collected in questionnaire at baseline and 12 month follow up visits.
|
Baseline; 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean changes in ambulatory daytime SBP from baseline to 12-month;
Time Frame: Baseline; 12 months
|
Ambulatory daytime SBP will be measured according to 24-hour ABPM.
|
Baseline; 12 months
|
Mean changes in ambulatory daytime DBP from baseline to 12-month;
Time Frame: Baseline; 12 months
|
Ambulatory daytime DBP will be measured according to 24-hour ABPM.
|
Baseline; 12 months
|
Mean changes in ambulatory nighttime SBP from baseline to 12-month;
Time Frame: Baseline; 12 months
|
Ambulatory nighttime SBP will be measured according to 24-hour ABPM.
|
Baseline; 12 months
|
Mean changes in ambulatory nighttime DBP from baseline to 12-month;
Time Frame: Baseline; 12 months
|
Ambulatory nighttime DBP will be measured according to 24-hour ABPM.
|
Baseline; 12 months
|
Mean changes in BMI from baseline to 12-month;
Time Frame: Baseline; 12 months
|
BMI will be measured by dividing weight in kilograms by height in metres squared.
|
Baseline; 12 months
|
Changes in physical activity level from baseline to 12-month;
Time Frame: Baseline; 12 months
|
We will measure the change in self-reported physical activity scale through questionnaire from baseline to 12 months.
|
Baseline; 12 months
|
Changes in smoking proportions from baseline to 12-month;
Time Frame: Baseline; 12 months
|
We will measure the change in self-reported smoking status through questionnaire from baseline to 12 months.
|
Baseline; 12 months
|
Proportions of patients with major cardiovascular events during follow-up period.
Time Frame: Baseline; 12 months
|
Major cardiovascular events are defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for heart failure.
|
Baseline; 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shengshou Hu, PhD, National Center for Cardiovascular Diseases
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2023
Primary Completion (Anticipated)
June 30, 2024
Study Completion (Anticipated)
June 30, 2024
Study Registration Dates
First Submitted
October 27, 2022
First Submitted That Met QC Criteria
October 29, 2022
First Posted (Actual)
November 4, 2022
Study Record Updates
Last Update Posted (Actual)
November 4, 2022
Last Update Submitted That Met QC Criteria
October 29, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-GSP-GG-21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on CHESS intervention
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Completed
-
Duke UniversityNational Cancer Institute (NCI)CompletedAdvanced CancerUnited States
-
Central Institute of Mental Health, MannheimMunich Chess academyRecruitingChildren and Adolescents Inpatient in Psychiatric HospitalGermany
-
University of Wisconsin, MadisonNational Institute of Nursing Research (NINR)Completed
-
University of Wisconsin, MadisonNational Institutes of Health (NIH)Completed
-
University of Wisconsin, MadisonNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Drinking | TelemedicineUnited States
-
University of Milano BicoccaRecruitingMild Cognitive Impairment | Subjective Cognitive DeclineItaly
-
New York Presbyterian HospitalUniversity of Wisconsin, MadisonUnknownLiver Diseases, AlcoholicUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed